Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 16, 2016. The report serves as a notification to the market regarding a transfer of shares out of the company's treasury.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to treasury shares.
- Shares Transferred: 33,300,000 Ordinary Shares (25 pence each).
- Transfer Price: £15.07 pence per Ordinary Share.
- Purpose: To satisfy awards under the Deferred Annual Bonus Plan, Performance Share Plan, and Share Value Plan via the GlaxoSmithKline Employee Benefit Trust.
- Issued Share Capital (Post-Transfer): 5,368,238,025 Ordinary Shares.
- Treasury Shares (Post-Transfer): 458,205,950 Ordinary Shares.
- Total Voting Rights: 4,910,032,075.
Material Changes
The primary material change is the reduction of treasury shares held by the company by 33,300,000 units following the transfer to the Employee Benefit Trust on December 15, 2016. Consequently, the total number of voting rights was updated to 4,910,032,075.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a procedural notification pursuant to the Financial Conduct Authority's Listing Rule 12.6.4.
Key Facts for Investor Verification
- Verify the updated total voting rights count of 4,910,032,075 for compliance with Disclosure and Transparency Rules.
- Confirm the reduction in treasury shares to 458,205,950 following the December 15, 2016 transfer.
- Note that the transfer price of £15.07 pence per share was used for the transaction with the Employee Benefit Trust.